ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Aptalis Pharmaceutical Technologies 

100 Somerset Corporate Boulevard
Suite 2000
Bridgewater  New Jersey  08807  U.S.A.
Phone: 1-908-429-4479, Ext 4177 Fax: n/a


SEARCH JOBS

Aptalis Pharmatech, Inc., is a wholly owned subsidiary of Forest Laboratories (NYSE: FRX) focused on developing high-value products with robust, defensible proprietary positions that grow the commercial value of our partners' portfolios.

We have a variety of products available for licensing across multiple therapeutic categories and collaborate with our partners to develop customized, value-added Rx and OTC products.

We develop and manufacture enhanced pharmaceutical products based on our broad range of proprietary oral drug delivery platforms, including:

1) Taste masking ODTs,
2) Bioavailability enhancement, and
3) Customized drug release.

We utilize these technologies to develop novel prescription and OTC products that have advantages over existing products and address unmet medical needs.

Our integrated R&D and manufacturing teams in the U.S. and Europe work with our partners from formulation through scale-up and commercial-scale manufacturing.

Our track record of success includes over 40 products that are commercialized around the world by our partners. To learn more speak with one of our licensing representatives, or visit: www.AptalisPharmaceuticalTechnologies.com.

Aptalis Pharmaceutical Technologies is focused on developing high-value products with robust, defensible proprietary positions that grow the commercial value of our partners' portfolios. We have a variety of products available for licensing across multiple therapeutic categories and collaborate with our partners to develop customized, value-added Rx and OTC products. Key products available for out-licensing are:

Ondansetron ER
Ondansetron ER is the first once-a-day formulation of the leading US oral 5-HT3 anti-emetic that provides therapeutic improvement over current treatments. 5-HT3 category prescriptions have a combined annual growth rate (CAGR) of 41%.

• Patient benefits: Single dose formulation is designed to minimize side effects of therapy and promote patient adherence, improving treatment results, and to reduce emesis-related patient anxiety, a risk factor for radiation-induced nausea and vomiting (RINV)

• Clinician benefits: Ondansetron ER is designed to provide therapeutic improvement over current treatments as identified by clinicians in market research

AdvaTab® Paracetamol (Acetaminophen) orally disintegrating tablet (ODT)
Launch-ready and formulated in a range of strengths for adult and pediatric dosing, AdvaTab Acetaminophen is a convenient, patient-friendly OTC pain reliever. AdvaTab Paracetamol (Acetaminophen) ODT is part of a new segment in the in the popular analgesic OTC market in the US and worldwide, by leveraging a successfully formulated and patient-friendly fast dissolving ODT.

Product developed according to European Pharmacopeia (EP) standards, complies with US OTC monograph standards, and is shown to be bioequivalent to the reference product. AdvaTab Acetaminophen ODT can be formulated in a range of dosages (80mg-500mg).

AdvaTab Temazepam ODT
Enhance your pipeline in a growing category with a novel, patient-friendly dosage form of a top-selling sleep aid. AdvaTab Temazepam is the first ODT formulation of a highly prescribed benzodiazepine. AdvaTab Temazepam is formulated in a convenient patient-friendly dosage form, potentially creating a new segment for the growing Rx sleep-aid market.

• 8.4 million US Temazepam prescriptions annually (IMS 2009-2010)
• 5% category compound annual growth rate (CAGR)

AdvaTab Hydrocodone / Acetaminophen ODT
The proprietary ODT formulation of Hydrocodone / Acetaminophen creates the opportunity for a partner to grow a new segment of the growing Rx pain market with the first and only ODT formulation of the most-prescribed drug combination in the US.*

As the first ODT formulation of the most-prescribed drug combination in the US (120 million prescriptions annually**), AdvaTab Hydrocodone / Acetaminophen fast dissolving ODT creates a unique market segment for a convenient, patient-friendly dosage form that facilitates accurate dosing and easier administration.

Formulated in two convenient dosage strengths, AdvaTab Hydrocodone / Acetaminophen's formulation and manufacturing processes are scalable achieve multiple dosage strengths.

*Based on information currently available in the public domain
**IMS data

Intellectual property
Our owned and in-licensed patent portfolio consists of over 900 granted patents and pending applications.

This portfolio is composed of patents with claims directed to our formulation technologies and related materials, processes, equipment and methods of manufacture. We also have many product-related patents, which contain more specific claims directed to particular drugs or classes of drugs in combination with our formulation technology.

Aptalis Pharmaceutical Technologies endeavors to offer the most effective patent protection possible to our partners based on our broad and diversified portfolio of Pharmaceutical Technologies.


 Key Statistics


Email: arecupero@aptalispharma.com
Ownership: Public

Web Site: Aptalis Pharmaceutical Technologies
Employees: 1,000
Symbol: FRX
 



Industry
Pharmaceutical

Segment
Drug Delivery





 Company News
Forest Laboratories, Inc. (FRX) Sets $1.8 Billion High Yield Bond Deal To Back Aptalis Pharmaceutical Technologies Buy 1/28/2014 7:48:18 AM
Forest Laboratories, Inc. (FRX) Scoops Up Aptalis Pharmaceutical Technologies For $2.9 Billion Cash 1/8/2014 7:29:53 AM
Bridgewater-Based Aptalis Pharmaceutical Technologies Files To Raise $500 Million In IPO 12/27/2013 6:38:49 AM
Novamedica Signs Distribution Agreement With Aptalis Pharmaceutical Technologies To Develop And Commercialize Gastrointestinal Pharmaceutical Products In Russia 12/5/2013 10:00:00 AM
Specialty Drugmaker Aptalis Pharmaceutical Technologies Carries a Hefty $3 Billion Price Tag, Any Takers? 8/7/2013 5:23:00 PM
Aptalis Pharmaceutical Technologies Co-Sponsors 2013 Controlled Release Society's Young Investigator Award at 40th Annual Meeting and Exposition 7/18/2013 12:27:54 PM
Aptalis Pharmaceutical Technologies Launches PYLERA® in France: A Therapeutic Alternative for Eradicating Helicobacter Pylori and Preventing Relapse of H. Pylori Associated Peptic Ulcers 4/11/2013 11:39:17 AM
Aptalis Pharmaceutical Technologies Expands Licensing Team 2/13/2013 2:24:33 PM
Aptalis Pharmaceutical Technologies Announces Results of Phase 3 Studies of Aeroquin™ (Levofloxacin Solution for Inhalation) Among Patients With Cystic Fibrosis and Chronic Lung Infection 1/7/2013 10:07:28 AM
Aptalis Pharmaceutical Technologies Announces European Commission Approval for a New Oral Granule Formulation of Viread® 12/13/2012 11:27:44 AM
12345